Cargando…

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown-Burke, Fiona, Hwang, Inah, Sloan, Shelby, Hinterschied, Claire, Helmig-Mason, JoBeth, Long, Mackenzie, Chan, Wing Keung, Prouty, Alexander, Chung, Ji-Hyun, Zhang, Yang, Singh, Satishkumar, Youssef, Youssef, Bhagwat, Neha, Chen, Zhengming, Chen-Kiang, Selina, Di Liberto, Maurizio, Elemento, Olivier, Sehgal, Lalit, Alinari, Lapo, Vaddi, Kris, Scherle, Peggy, Lapalombella, Rosa, Paik, Jihye, Baiocchi, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582835/
https://www.ncbi.nlm.nih.gov/pubmed/37327122
http://dx.doi.org/10.1182/bloodadvances.2023009906
_version_ 1785122422166388736
author Brown-Burke, Fiona
Hwang, Inah
Sloan, Shelby
Hinterschied, Claire
Helmig-Mason, JoBeth
Long, Mackenzie
Chan, Wing Keung
Prouty, Alexander
Chung, Ji-Hyun
Zhang, Yang
Singh, Satishkumar
Youssef, Youssef
Bhagwat, Neha
Chen, Zhengming
Chen-Kiang, Selina
Di Liberto, Maurizio
Elemento, Olivier
Sehgal, Lalit
Alinari, Lapo
Vaddi, Kris
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert A.
author_facet Brown-Burke, Fiona
Hwang, Inah
Sloan, Shelby
Hinterschied, Claire
Helmig-Mason, JoBeth
Long, Mackenzie
Chan, Wing Keung
Prouty, Alexander
Chung, Ji-Hyun
Zhang, Yang
Singh, Satishkumar
Youssef, Youssef
Bhagwat, Neha
Chen, Zhengming
Chen-Kiang, Selina
Di Liberto, Maurizio
Elemento, Olivier
Sehgal, Lalit
Alinari, Lapo
Vaddi, Kris
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert A.
author_sort Brown-Burke, Fiona
collection PubMed
description Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival remains at a dismal 3 to 8 months. There is a major unmet need to identify new therapeutic approaches that are well tolerated to improve treatment outcomes and quality of life. The protein arginine methyltransferase 5 (PRMT5) enzyme is overexpressed in MCL and promotes growth and survival. Inhibition of PRMT5 drives antitumor activity in MCL cell lines and preclinical murine models. PRMT5 inhibition reduced the activity of prosurvival AKT signaling, which led to the nuclear translocation of FOXO1 and modulation of its transcriptional activity. Chromatin immunoprecipitation and sequencing identified multiple proapoptotic BCL-2 family members as FOXO1-bound genomic loci. We identified BAX as a direct transcriptional target of FOXO1 and demonstrated its critical role in the synergy observed between the selective PRMT5 inhibitor, PRT382, and the BCL-2 inhibitor, venetoclax. Single-agent and combination treatments were performed in 9 MCL lines. Loewe synergy scores showed significant levels of synergy in most MCL lines tested. Preclinical, in vivo evaluation of this strategy in multiple MCL models showed therapeutic synergy with combination venetoclax/PRT382 treatment with an increased survival advantage in 2 patient-derived xenograft models (P ≤ .0001, P ≤ .0001). Our results provide mechanistic rationale for the combination of PRMT5 inhibition and venetoclax to treat patients with MCL.
format Online
Article
Text
id pubmed-10582835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-105828352023-10-19 PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma Brown-Burke, Fiona Hwang, Inah Sloan, Shelby Hinterschied, Claire Helmig-Mason, JoBeth Long, Mackenzie Chan, Wing Keung Prouty, Alexander Chung, Ji-Hyun Zhang, Yang Singh, Satishkumar Youssef, Youssef Bhagwat, Neha Chen, Zhengming Chen-Kiang, Selina Di Liberto, Maurizio Elemento, Olivier Sehgal, Lalit Alinari, Lapo Vaddi, Kris Scherle, Peggy Lapalombella, Rosa Paik, Jihye Baiocchi, Robert A. Blood Adv Lymphoid Neoplasia Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival remains at a dismal 3 to 8 months. There is a major unmet need to identify new therapeutic approaches that are well tolerated to improve treatment outcomes and quality of life. The protein arginine methyltransferase 5 (PRMT5) enzyme is overexpressed in MCL and promotes growth and survival. Inhibition of PRMT5 drives antitumor activity in MCL cell lines and preclinical murine models. PRMT5 inhibition reduced the activity of prosurvival AKT signaling, which led to the nuclear translocation of FOXO1 and modulation of its transcriptional activity. Chromatin immunoprecipitation and sequencing identified multiple proapoptotic BCL-2 family members as FOXO1-bound genomic loci. We identified BAX as a direct transcriptional target of FOXO1 and demonstrated its critical role in the synergy observed between the selective PRMT5 inhibitor, PRT382, and the BCL-2 inhibitor, venetoclax. Single-agent and combination treatments were performed in 9 MCL lines. Loewe synergy scores showed significant levels of synergy in most MCL lines tested. Preclinical, in vivo evaluation of this strategy in multiple MCL models showed therapeutic synergy with combination venetoclax/PRT382 treatment with an increased survival advantage in 2 patient-derived xenograft models (P ≤ .0001, P ≤ .0001). Our results provide mechanistic rationale for the combination of PRMT5 inhibition and venetoclax to treat patients with MCL. The American Society of Hematology 2023-06-20 /pmc/articles/PMC10582835/ /pubmed/37327122 http://dx.doi.org/10.1182/bloodadvances.2023009906 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Lymphoid Neoplasia
Brown-Burke, Fiona
Hwang, Inah
Sloan, Shelby
Hinterschied, Claire
Helmig-Mason, JoBeth
Long, Mackenzie
Chan, Wing Keung
Prouty, Alexander
Chung, Ji-Hyun
Zhang, Yang
Singh, Satishkumar
Youssef, Youssef
Bhagwat, Neha
Chen, Zhengming
Chen-Kiang, Selina
Di Liberto, Maurizio
Elemento, Olivier
Sehgal, Lalit
Alinari, Lapo
Vaddi, Kris
Scherle, Peggy
Lapalombella, Rosa
Paik, Jihye
Baiocchi, Robert A.
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title_full PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title_fullStr PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title_full_unstemmed PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title_short PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
title_sort prmt5 inhibition drives therapeutic vulnerability to combination treatment with bcl-2 inhibition in mantle cell lymphoma
topic Lymphoid Neoplasia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582835/
https://www.ncbi.nlm.nih.gov/pubmed/37327122
http://dx.doi.org/10.1182/bloodadvances.2023009906
work_keys_str_mv AT brownburkefiona prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT hwanginah prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT sloanshelby prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT hinterschiedclaire prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT helmigmasonjobeth prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT longmackenzie prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT chanwingkeung prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT proutyalexander prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT chungjihyun prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT zhangyang prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT singhsatishkumar prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT youssefyoussef prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT bhagwatneha prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT chenzhengming prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT chenkiangselina prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT dilibertomaurizio prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT elementoolivier prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT sehgallalit prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT alinarilapo prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT vaddikris prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT scherlepeggy prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT lapalombellarosa prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT paikjihye prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma
AT baiocchiroberta prmt5inhibitiondrivestherapeuticvulnerabilitytocombinationtreatmentwithbcl2inhibitioninmantlecelllymphoma